Tag Archives: Stephen Willey
Analysts’ Top Healthcare Picks: Zymeworks (ZYME), ThermoGenesis Holdings (THMO)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME – Research Report), ThermoGenesis Holdings (THMO – Research Report) and SAGE Therapeutics (SAGE – Research Report) with bullish sentiments. Zymeworks
Stifel Nicolaus Reiterates a Buy Rating on GlycoMimetics (GLYC)
Stifel Nicolaus analyst Stephen Willey reiterated a Buy rating on GlycoMimetics (NASDAQ: GLYC) on August 10 and set a price target of $24. The company’s shares closed on Friday at $14.45. According to TipRanks.com, Willey is a 5-star analyst with
Ionis Pharmaceuticals Inc (IONS) Receives a Hold from Stifel Nicolaus
In a report released yesterday, Stephen Willey from Stifel Nicolaus reiterated a Hold rating on Ionis Pharmaceuticals Inc (NASDAQ: IONS), with a price target of $48. The company’s shares closed yesterday at $43.65. According to TipRanks.com, Willey is a 5-star
Stifel Nicolaus Thinks Achaogen’s Stock is Going to Recover
In a report released today, Stephen Willey from Stifel Nicolaus reiterated a Buy rating on Achaogen (NASDAQ: AKAO), with a price target of $14. The company’s shares closed yesterday at $7.05, close to its 52-week low of $6.23. According to
Akcea Therapeutics Inc (AKCA) Receives a Hold from Stifel Nicolaus
In a report released yesterday, Stephen Willey from Stifel Nicolaus reiterated a Hold rating on Akcea Therapeutics Inc (NASDAQ: AKCA). The company’s shares closed yesterday at $34.19, close to its 52-week high of $38.06. According to TipRanks.com, Willey is a
Stifel Nicolaus Downgrades Alexion Pharmaceuticals (ALXN) to Hold
Alexion Pharmaceuticals (NASDAQ: ALXN) received a Hold rating and a $130 price target from Stifel Nicolaus analyst Stephen Willey today. The company’s shares closed yesterday at $123.36. According to TipRanks.com, Willey is a 5-star analyst with an average return of
